Catalog No.
DXX02201
Expression system
Mammalian Cells
Species reactivity
Gram negative bacteria
Host species
Human
Isotype
IgM-kappa
Clonality
Monoclonal
Target
Endotoxin (Lipid A)
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
HA-1A, centoxin, septomonab, CAS: 138661-01-5
Clone ID
Nebacumab
Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal, PMID: 7521827
Centoxin, PMID: 8435673
Marketed therapeutic antibodies compendium, PMID: 22531442
The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin, PMID: 22531443
Biotechnology and clinical trials, PMID: 11865440
Update on monoclonal antibody therapy in the gram-negative sepsis syndrome, PMID: 1429060
Antiendotoxin monoclonal antibodies. What future now?, PMID: 7848542
Assessment of biotechnology drugs: what are the issues?, PMID: 10538922
Monoclonal antibodies to endotoxin in the management of sepsis, PMID: 8317126
Issues in the adjunct therapy of severe sepsis, PMID: 8877531
Anti-endotoxin monoclonal antibodies, PMID: 1552929
Anti-endotoxin monoclonal antibodies, PMID: 1552919
Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies, PMID: 8469619
Looking back on HA-1A, PMID: 7979833
Advances in the therapy for sepsis in children, PMID: 9057790
Sepsis therapy still shocking, PMID: 9219250
P & T Committee response to evolving technologies: preparing for the launch of high-tech, high-cost products. Roundtable discussion, PMID: 10117768
Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome, PMID: 8501580
Antiendotoxin antibodies: a dead end?, PMID: 8198349
Anti-endotoxin monoclonal antibodies--a second look, PMID: 1552918
Economic assessment of drugs in Spain, PMID: 10146905
Management of generalized faecal peritonitis, PMID: 1294127
Perspectives for the future, PMID: 8227736
New treatments for sepsis, PMID: 8365201
[Immunotherapy in sepsis syndrome], PMID: 1603159
New drugs on the horizon, PMID: 1534032
The economics of gene therapy and of pharmacogenetics, PMID: 11873384
Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies, PMID: 1611812
The search for a magic bullet to fight sepsis, PMID: 8474207
Immunotherapy of sepsis, PMID: 8474114
Lessons learned from clinical trials on monoclonal anti-endotoxin antibody, PMID: 8203986
Management of pre-eclampsia, PMID: 8679381
New treatments for septic shock, PMID: 1741367
Monoclonal antiendotoxin agent HA-1A (Centoxin), PMID: 8093933
[Septomonab (Centoxin) in the treatment of gram-negative septicemia], PMID: 8497944
Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI, PMID: 8024362
Thoughts on drug development, PMID: 1634635
Antiendotoxin therapy in sepsis, PMID: 8398040
[Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis], PMID: 8437630
Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock, PMID: 8361858
Challenges to the economic evaluation of new biotechnological interventions in healthcare, PMID: 10539393
HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis, PMID: 1578120
Clinical trials of immunotherapy for sepsis, PMID: 1597020
Human monoclonal antibodies in sepsis, PMID: 1791872
Anti-lipid A monoclonal antibody centoxin (HA-1A) binds to a wide variety of hydrophobic ligands, PMID: 9453659
Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide, PMID: 8418211
Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5, PMID: 8143464
Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients, PMID: 8417245
A controlled trial of HA-1A in a canine model of gram-negative septic shock, PMID: 8474201
Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels, PMID: 1431255
For research use only. Not for human or drug use.
